We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Conmed (CNMD) Down 12.2% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Conmed (CNMD - Free Report) . Shares have lost about 12.2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Conmed due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
CNMD's Q4 Earnings & Sales Beat Estimates, ‘25 Outlook Weak
CONMED delivered fourth-quarter 2024 adjusted earnings per share of $1.34, which beat the Zacks Consensus Estimate of $1.20 by 11.7%. The bottom line improved 26.4% from the year-ago level.
GAAP earnings per share for the quarter was $1.08 compared with $1.50 in the year-ago period.
CNMD’s Revenues in Detail
CONMED’s revenues totaled $345.9 million, up 5.8% year over year. The top line beat the Zacks Consensus Estimate by 1.4%. At constant exchange rate (CER), revenues increased 6%.
The top line was driven primarily by strength in the General Surgery segment and continued demand for innovative products like AirSeal.
CNMD’s Full-Year 2024 Results
For 2024, CNMD’s revenues totaled $1.31 billion, up 5% year over year on a reported basis and 5.3% on a constant currency basis.
CNMD’s full-year adjusted EPS was $4.17, up 20.9% compared to 2023.
CONMED’s Segmental Details
Revenues in the Orthopedic Surgery segment totaled $139 million, up 1.8% from the year-ago level on a reported basis. At CER, revenues increased 2.4%.
Sales improved 5.2% on a reported basis in the United States. The figure declined 0.2% (up 0.6% at CER) year over year in international markets.
Revenues in the General Surgery segment amounted to $206.9 million, up 8.6% year over year on a reported basis and 8.7% at CER. U.S. sales increased 7.4% year over year. International sales increased 11.9% on a reported basis (up 12% at CER).
Sales by Geography
Sales in the United States totaled $203.3 million, up 6.8% year over year. International sales amounted to $142.6 million, up 4.4% year over year on a reported basis and up 5% at CER.
Margins
CONMED’s gross profit improved 8.9% year over year to $198.3 million. The gross margin improved 160 basis points to 57.3%.
Selling & administrative expenses increased 12.5% year over year to $132.7 million. Research and development expenses decreased 6.1% year over year to $13.2 million.
The company recorded an operating income of $52.5 million compared with $50.2 million in the prior-year quarter. The operating margin was 15.2%, down 10 basis points.
Financial Position
CNMD exited the fourth quarter with a cash balance of $24.5 million compared with $38.5 million in the previous quarter.
Cash flow provided from operations in the reported quarter was $43.3 million compared with $56.4 million in the fourth quarter of 2023.
2025 Guidance Issued
CONMED provided its revenue and earnings guidance for 2025.
The company expects full-year 2025 revenues between $1.34 billion and $1.37 billion. This represents year-over-year constant-currency growth of approximately 4% to 6%.
The company also expects 2025 adjusted earnings per share in the range of $4.25-$4.40.
The company also provided revenue guidance for the first quarter of 2025. CNMD expects reported sales in the first quarter between $310 million and $316 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -19.2% due to these changes.
VGM Scores
At this time, Conmed has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Conmed has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Conmed (CNMD) Down 12.2% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Conmed (CNMD - Free Report) . Shares have lost about 12.2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Conmed due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
CNMD's Q4 Earnings & Sales Beat Estimates, ‘25 Outlook Weak
CONMED delivered fourth-quarter 2024 adjusted earnings per share of $1.34, which beat the Zacks Consensus Estimate of $1.20 by 11.7%. The bottom line improved 26.4% from the year-ago level.
GAAP earnings per share for the quarter was $1.08 compared with $1.50 in the year-ago period.
CNMD’s Revenues in Detail
CONMED’s revenues totaled $345.9 million, up 5.8% year over year. The top line beat the Zacks Consensus Estimate by 1.4%. At constant exchange rate (CER), revenues increased 6%.
The top line was driven primarily by strength in the General Surgery segment and continued demand for innovative products like AirSeal.
CNMD’s Full-Year 2024 Results
For 2024, CNMD’s revenues totaled $1.31 billion, up 5% year over year on a reported basis and 5.3% on a constant currency basis.
CNMD’s full-year adjusted EPS was $4.17, up 20.9% compared to 2023.
CONMED’s Segmental Details
Revenues in the Orthopedic Surgery segment totaled $139 million, up 1.8% from the year-ago level on a reported basis. At CER, revenues increased 2.4%.
Sales improved 5.2% on a reported basis in the United States. The figure declined 0.2% (up 0.6% at CER) year over year in international markets.
Revenues in the General Surgery segment amounted to $206.9 million, up 8.6% year over year on a reported basis and 8.7% at CER. U.S. sales increased 7.4% year over year. International sales increased 11.9% on a reported basis (up 12% at CER).
Sales by Geography
Sales in the United States totaled $203.3 million, up 6.8% year over year. International sales amounted to $142.6 million, up 4.4% year over year on a reported basis and up 5% at CER.
Margins
CONMED’s gross profit improved 8.9% year over year to $198.3 million. The gross margin improved 160 basis points to 57.3%.
Selling & administrative expenses increased 12.5% year over year to $132.7 million. Research and development expenses decreased 6.1% year over year to $13.2 million.
The company recorded an operating income of $52.5 million compared with $50.2 million in the prior-year quarter. The operating margin was 15.2%, down 10 basis points.
Financial Position
CNMD exited the fourth quarter with a cash balance of $24.5 million compared with $38.5 million in the previous quarter.
Cash flow provided from operations in the reported quarter was $43.3 million compared with $56.4 million in the fourth quarter of 2023.
2025 Guidance Issued
CONMED provided its revenue and earnings guidance for 2025.
The company expects full-year 2025 revenues between $1.34 billion and $1.37 billion. This represents year-over-year constant-currency growth of approximately 4% to 6%.
The company also expects 2025 adjusted earnings per share in the range of $4.25-$4.40.
The company also provided revenue guidance for the first quarter of 2025. CNMD expects reported sales in the first quarter between $310 million and $316 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -19.2% due to these changes.
VGM Scores
At this time, Conmed has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Conmed has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.